Titan Pharmaceuticals (Titan Pharmaceuticals) Growth Rank : 2 (As of May. 07, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals Growth Rank?

Titan Pharmaceuticals has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Titan Pharmaceuticals's Growth Rank

For the Biotechnology subindustry, Titan Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Titan Pharmaceuticals's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Growth Rank distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Growth Rank falls into.

Titan Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

TN70:Germany

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Executives

Seow Gim Shen	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd.	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo	director	1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey	director	3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg	director	710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi	director	44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe	director, officer: President and COO	400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong	10 percent owner	NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar	director, 10 percent owner, officer: Chief Executive Officer	VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc	other: Member of 10% owner group	1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers	director	630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab	director	C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin	director, officer: Executive Chairman	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg	officer: See Remarks	400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080